According to the latest report in the journal Nature Communications, researchers from the University of Wisconsin-Madison in the United States have identified two key genes, GJB2 and BET1L, that hinder the success of gene editing therapy by screening over 19,000 genes. After suppressing these two genes, the efficiency of gene editing increased more than 3.5-fold in retinal cells of patients with inherited eye diseases. The study, which lasted six years, identified target genes through genome-wide screening and validation, providing a new direction for optimizing gene editing therapy. The transport efficiency of lipid nanoparticles, used as delivery vehicles for gene editing tools, is influenced by intracellular gene regulation. This discovery may have synergistic effects on fields such as mRNA vaccines and cancer immunotherapy.